Mar 20, 2025
Eupraxia Pharmaceuticals Reports Fourth Quarter 2024 Financial Results
Feb 18, 2025
Eupraxia Pharmaceuticals Announces CFO Succession
Nov 20, 2024
Eupraxia's DiffuSphere(TM) Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months
Nov 14, 2024
Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting
Nov 13, 2024
Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November 15, 2024
Nov 12, 2024
Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
Nov 07, 2024
Eupraxia Pharmaceuticals Reports Third Quarter 2024 Financial Results
Oct 31, 2024
Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 Million
Oct 28, 2024
Eupraxia Pharmaceuticals to Present at American College of Gastroenterology Annual Scientific Meeting 2024
Oct 15, 2024
Lancet Rheumatology Publishes Phase 2b Data on Eupraxia Pharmaceuticals' EP-104IAR for the Treatment of Knee Osteoarthritis
Oct 10, 2024
Eupraxia Pharmaceuticals to Present at United European Gastroenterology Week 2024
Oct 02, 2024
Eupraxia Pharmaceuticals Strengthens Senior Management Team
Sep 19, 2024
Eupraxia Pharmaceuticals to Present at 20th ISDE World Congress for Esophageal Diseases
Sep 11, 2024
Eupraxia Pharmaceuticals Announces Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
Sep 04, 2024
Eupraxia Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Aug 07, 2024
Eupraxia Pharmaceuticals Reports Second Quarter 2024 Financial Results
Aug 02, 2024
Eupraxia Pharmaceuticals Announces New C$12 Million Convertible Debt Facility
Jul 08, 2024
Eupraxia Pharmaceuticals to Present at Controlled Release Society 2024 Annual Meeting and Expo
Jul 03, 2024
Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Exploring the Rapid Rise of Osteoarthritis" on July 9, 2024
Jun 06, 2024
Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders